Stock comparison
Genmab A/S
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 72B | RMD |
| Benjamin Graham | 64C | 75B | RMD |
| Philip Fisher | 48D | 75B | RMD |
| Peter Lynch | 25F | 58C | RMD |
| Joel Greenblatt | 76B | 47D | GMAB |
| Charlie Munger | 68C | 69B | RMD |
| Terry Smith | 71C | 73B | RMD |
Side-by-side metrics
| Metric | GMAB | RMD |
|---|---|---|
| Market cap | $16.5B | $30.18B |
| P/E (TTM) | 6.2x | 19.6x |
| EV/EBIT | 12.0x | 17.1x |
| ROIC (TTM) | 43.78% | 19.63% |
| Gross margin | 93.88% | 61.69% |
| Net margin | 18.23% | 27.44% |
| Revenue CAGR 5y | -18.45% | 12.64% |
| EPS CAGR 5y | -23.48% | 30.73% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 19.6x+69%
- ROIC (TTM)43.78%vs 19.63%+55%
- Debt / Equity0.1xvs 0.1x+43%
- Gross margin93.88%vs 61.69%+34%
RMD leads on
- EPS CAGR 5y30.73%vs -23.48%+176%
- Revenue CAGR 5y12.64%vs -18.45%+169%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $16.5B+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.